NCT07527208 The Meta-SHIFT Study: How Metabolic Shift Shapes Human Immunometabolism - a Fasting Trial
| NCT ID | NCT07527208 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cornell University |
| Condition | Fasting |
| Study Type | INTERVENTIONAL |
| Enrollment | 28 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2026-08-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 28 participants in total. It began in 2026-06-01 with a primary completion date of 2026-08-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
During fasting, the body shifts from using carbohydrates to relying more on fat as its main source of energy. This process is known as the 'metabolic shift'. Fat tissue helps supply this energy by breaking down stored fat into fatty acids, which are released into the bloodstream and transported to organs throughout the body. In addition to fatty acids, many other substances in the blood (such as metabolites) change during fasting to help maintain normal body function. Immune cells also circulate in the blood and play an important role in protecting the body against infections and diseases such as cancer. However, it is not yet well understood how the metabolic shift during fasting affects immune cell function. The purpose of this study is to investigate how 24 hours of fasting influences immune cell metabolism and function.
Eligibility Criteria
Inclusion Criteria: * Apparently healthy * Age 18-40y at the time of recruitment * BMI ≥ 18.5 and ≤ 24.9 kg/m2 * Willing to participate in all study activities during the 3-day intervention * Signed informed consent Exclusion Criteria: * Diagnosed with any chronic medical condition that can interfere with the study outcome (e.g., cardiovascular disease, cancer, diabetes mellitus type 1 or 2, liver disease, pulmonary disease, renal disease, inflammatory bowel disease, thyroid disease, long COVID, PASC) * Bleeding disorder (e.g., Hemophilia A/B, Von Willebrand Disease, or low platelets), current anemia or current use of blood thinners or anticoagulants (e.g. warfarin, heparin) * Any acute or chronic infection disease or fever in the past month * Antibiotic use in the past 2 months * Use of any prescribed medications (incl. GLP-1 agonists), except for contraceptives * Usage of recreational drugs in the last three months * Unstable body weight (weight gain or loss \>5% of total BW in the past three months) * Following any restrictive diet within one month of starting the study (for example a ketogenic diet or weight loss diet) * Fasted for 16 hours or longer in the past week * History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating disorder) * Allergic to one or more components of the standardized meal and/or shake (i.e., milk, wheat, and soy) * Average alcohol intake that exceeds 1 consumption/day or 7 consumptions/week over the past month * Tobacco smoker or regular use of nicotine products * Donated or intend to donate blood from 2 months before the study until the end of the study * Being pregnant or lactating * Participation in another biomedical study during this study
Contact & Investigator
Sander Kersten, Ph.D.
PRINCIPAL INVESTIGATOR
Cornell University
Frequently Asked Questions
Who can join the NCT07527208 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Fasting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07527208 currently recruiting?
Yes, NCT07527208 is actively recruiting participants. Contact the research team at meta-shift@cornell.edu for enrollment information.
Where is the NCT07527208 trial being conducted?
This trial is being conducted at Ithaca, United States.
Who is sponsoring the NCT07527208 clinical trial?
NCT07527208 is sponsored by Cornell University. The principal investigator is Sander Kersten, Ph.D. at Cornell University. The trial plans to enroll 28 participants.